Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

708 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trial.
Shi W, Jiang T, Nuciforo P, Hatzis C, Holmes E, Harbeck N, Sotiriou C, Peña L, Loi S, Rosa DD, Chia S, Wardley A, Ueno T, Rossari J, Eidtmann H, Armour A, Piccart-Gebhart M, Rimm DL, Baselga J, Pusztai L. Shi W, et al. Among authors: pena l. Ann Oncol. 2017 Jan 1;28(1):128-135. doi: 10.1093/annonc/mdw434. Ann Oncol. 2017. PMID: 28177460 Free PMC article. Clinical Trial.
Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trial.
Shi W, Jiang T, Nuciforo P, Hatzis C, Holmes E, Harbeck N, Sotiriou C, Peña L, Loi S, Rosa DD, Chia S, Wardley A, Ueno T, Rossari J, Eidtmann H, Armour A, Piccart-Gebhart M, Rimm DL, Baselga J, Pusztai L. Shi W, et al. Among authors: pena l. Ann Oncol. 2018 Oct 1;29(10):2152. doi: 10.1093/annonc/mdx805. Ann Oncol. 2018. PMID: 29701764 Free PMC article. No abstract available.
Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trial.
Shi W, Jiang T, Nuciforo P, Hatzis C, Holmes E, Harbeck N, Sotiriou C, Peña L, Loi S, Rosa DD, Chia S, Wardley A, Ueno T, Rossari J, Eidtmann H, Armour A, Piccart-Gebhart M, Rimm DL, Baselga J, Pusztai L. Shi W, et al. Among authors: pena l. Ann Oncol. 2019 Jun 1;30(6):1018. doi: 10.1093/annonc/mdy530. Ann Oncol. 2019. PMID: 30624555 Free PMC article. No abstract available.
The 41-gene classifier TRAR predicts response of HER2 positive breast cancer patients in the NeoALTTO study.
Di Cosimo S, Triulzi T, Pizzamiglio S, De Cecco L, de Azambuja E, Fumagalli D, Putzai L, Harbeck N, Izquierdo M, Peña L, Daidone MG, Huober J, Gori S, Cinieri S, Torri V, Baselga J, Piccart M, de Braud FG, Apolone G, Verderio P, Tagliabue E. Di Cosimo S, et al. Among authors: pena l. Eur J Cancer. 2019 Sep;118:1-9. doi: 10.1016/j.ejca.2019.06.001. Epub 2019 Jul 5. Eur J Cancer. 2019. PMID: 31284184 Free article.
[Cancer].
GROSSMANN SIEGER E, PENA LB. GROSSMANN SIEGER E, et al. Among authors: pena lb. Rev Sanid Asist Soc. 1961 Mar;1(Suppl):133-88. Rev Sanid Asist Soc. 1961. PMID: 13960720 Spanish. No abstract available.
Antiviral and immunomodulatory effects of ouabain against Congenital Zika Syndrome model.
Madruga Carvalho DC, Dunn T, Campos RK, Tierney JA, Onyoni F, Agra Cavalcante-Silva LH, Pena LJ, Rodrigues-Mascarenhas S, Wu P, Weaver SC. Madruga Carvalho DC, et al. Among authors: pena lj. Mol Ther. 2024 Dec 13:S1525-0016(24)00820-7. doi: 10.1016/j.ymthe.2024.12.021. Online ahead of print. Mol Ther. 2024. PMID: 39674887
Ecological study to estimate the prevalence of patients with acid sphingomyelinase deficiency in Spain. PREVASMD study.
Villarrubia J, Morales M, Ceberio L, Vitoria I, Bellusci M, Quiñones I, Peña L, Ruiz de Valbuena M, O'Callaghan M; en representación del grupo de estudio PREVASMD. Villarrubia J, et al. Among authors: pena l. Rev Clin Esp (Barc). 2024 Nov 28:S2254-8874(24)00153-X. doi: 10.1016/j.rceng.2024.11.007. Online ahead of print. Rev Clin Esp (Barc). 2024. PMID: 39613101
708 results